MCID: MNN032
MIFTS: 54

Meningococcal Meningitis

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Meningitis

MalaCards integrated aliases for Meningococcal Meningitis:

Name: Meningococcal Meningitis 12 58 15 17 71 32
Meningitis, Meningococcal 74 43
Meningitis Meningococcal 54

Characteristics:

Orphanet epidemiological data:

58
meningococcal meningitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (New Zealand),1-9/1000000 (United States);

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Meningococcal Meningitis

Disease Ontology : 12 A bacterial meningitis that has material basis in Neisseria meningitidis infection.

MalaCards based summary : Meningococcal Meningitis, also known as meningitis, meningococcal, is related to meningococcemia and meningitis. An important gene associated with Meningococcal Meningitis is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Tuberculosis. The drugs Lactitol and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include testes, b cells and skin, and related phenotypes are fever and hypoglycorrhachia

Wikipedia : 74 Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis (also termed... more...

Related Diseases for Meningococcal Meningitis

Diseases related to Meningococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 meningococcemia 31.4 MBL2 CFP
2 meningitis 31.0 TLR9 TLR4 TLR2 MBL2 CFP C3
3 haemophilus influenzae 30.8 TLR2 CFH
4 neisseria meningitidis infection 30.2 TLR4 TLR2 MBL2 DHPS CFP C3
5 bacterial meningitis 30.0 TLR9 TLR4 TLR2 MBL2 CFP C3
6 membranoproliferative glomerulonephritis 30.0 CFP CFHR2 CFH C3
7 streptococcus pneumonia 29.9 TLR9 TLR4 TLR2
8 septic arthritis 29.9 TLR9 TLR4 TLR2
9 plague 29.9 TLR9 TLR4 TLR2
10 fungal infectious disease 29.9 TLR9 TLR4 TLR2
11 listeriosis 29.9 TLR4 TLR2 MBL2
12 candidiasis 29.7 TLR4 TLR2 MBL2
13 complement component 5 deficiency 29.6 CFP CFHR2 C4B C3
14 glomerulonephritis 29.4 TLR9 MBL2 CFP CFH C4B C3
15 otitis media 29.3 TLR4 TLR2 MBL2 C3
16 malaria 29.3 TLR9 TLR4 TLR2 MBL2 DHPS CFH
17 complement component 3 deficiency 29.1 MBL2 CFP CFHR2 C4B C3
18 eye disease 29.0 TLR4 TLR2 CFHR2 CFH C3
19 complement deficiency 28.8 MBL2 CFP CFHR2 CFH C7 C6
20 thrombocytopenia 28.8 TLR9 TLR4 TLR2 MBL2 CFH C3
21 systemic lupus erythematosus 28.2 TLR9 TLR4 TLR2 MBL2 CFHR2 CFH
22 meningococcal infection 10.6
23 pericarditis 10.5
24 branchiootic syndrome 1 10.4
25 mannose-binding lectin deficiency 10.4 MBL2 CFP
26 exanthem 10.4
27 anti-basement membrane glomerulonephritis 10.4 CFP CFHR2
28 endophthalmitis 10.3
29 waterhouse-friderichsen syndrome 10.3
30 immunodeficiency due to a late component of complement deficiency 10.3 C7 C6
31 ataxia and polyneuropathy, adult-onset 10.3
32 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
33 purpura 10.3
34 pleural empyema 10.3
35 atypical hemolytic uremic syndrome with complement gene abnormality 10.3 CFH C3
36 scalp dermatosis 10.3 TLR9 TLR2
37 central serous chorioretinopathy 10.3 CFH C4B
38 complement component 6 deficiency 10.3
39 disseminated intravascular coagulation 10.3
40 toxic shock syndrome 10.3
41 arthritis 10.3
42 vasculitis 10.3
43 genetic atypical hemolytic-uremic syndrome 10.2 CFH C3
44 diffuse glomerulonephritis 10.2 CFP C3
45 yemenite deaf-blind hypopigmentation syndrome 10.2
46 purpura fulminans 10.2
47 subdural empyema 10.2
48 paraplegia 10.2
49 pneumococcal meningitis 10.2
50 fungal keratitis 10.1 TLR4 TLR2

Graphical network of the top 20 diseases related to Meningococcal Meningitis:



Diseases related to Meningococcal Meningitis

Symptoms & Phenotypes for Meningococcal Meningitis

Human phenotypes related to Meningococcal Meningitis:

58 31 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 hypoglycorrhachia 58 31 hallmark (90%) Very frequent (99-80%) HP:0011972
3 increased csf protein 58 31 hallmark (90%) Very frequent (99-80%) HP:0002922
4 csf pleocytosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0012229
5 stiff neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0025258
6 nuchal rigidity 58 31 hallmark (90%) Very frequent (99-80%) HP:0031179
7 photophobia 58 31 frequent (33%) Frequent (79-30%) HP:0000613
8 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
9 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
10 sepsis 58 31 frequent (33%) Frequent (79-30%) HP:0100806
11 petechiae 58 31 frequent (33%) Frequent (79-30%) HP:0000967
12 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
13 elevated c-reactive protein level 58 31 frequent (33%) Frequent (79-30%) HP:0011227
14 projectile vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002587
15 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
16 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
17 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
18 irritability 58 31 occasional (7.5%) Occasional (29-5%) HP:0000737
19 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
20 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
21 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
22 drowsiness 58 31 occasional (7.5%) Occasional (29-5%) HP:0002329
23 papilledema 58 31 occasional (7.5%) Occasional (29-5%) HP:0001085
24 abnormality of the anterior fontanelle 58 31 occasional (7.5%) Occasional (29-5%) HP:0000236
25 seizure 31 occasional (7.5%) HP:0001250
26 cranial nerve paralysis 58 31 very rare (1%) Very rare (<4-1%) HP:0006824
27 neonatal respiratory distress 58 31 very rare (1%) Very rare (<4-1%) HP:0002643
28 stroke 58 31 very rare (1%) Very rare (<4-1%) HP:0001297
29 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
30 hypothermia 58 31 very rare (1%) Very rare (<4-1%) HP:0002045
31 shock 58 31 very rare (1%) Very rare (<4-1%) HP:0031273
32 acute disseminated intravascular coagulation 58 31 very rare (1%) Very rare (<4-1%) HP:0011880
33 seizures 58 Occasional (29-5%)
34 reduced consciousness/confusion 58 Frequent (79-30%)
35 purpura 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Meningococcal Meningitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.61 ATP2B3 C3 C4B C6 C7 CFH
2 renal/urinary system MP:0005367 9.28 BAMBI C3 C4B CFH DHPS MBL2

Drugs & Therapeutics for Meningococcal Meningitis

Drugs for Meningococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
2
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Zidovudine Approved Phase 4 30516-87-1 35370
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
7
leucovorin Approved Phase 4 58-05-9 6006 143
8
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
protease inhibitors Phase 4
12 HIV Protease Inhibitors Phase 4
13 BB 1101 Phase 4
14 Complement Factor H Phase 4
15 Vaccines Phase 4
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
17 Immunologic Factors Phase 4
18 Immunoglobulins Phase 4
19 Antibodies Phase 4
20 Cathartics Phase 4
21 Laxatives Phase 4
22 Gastrointestinal Agents Phase 4
23 Anti-Retroviral Agents Phase 4
24 Anti-HIV Agents Phase 4
25 Reverse Transcriptase Inhibitors Phase 4
26 Vitamin B Complex Phase 4
27 Folate Phase 4
28 Folic Acid Antagonists Phase 4
29 Dermatologic Agents Phase 4
30 Antirheumatic Agents Phase 4
31 Vitamin B9 Phase 4
32 Antibiotics, Antitubercular Phase 4
33
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
34
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
35
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
36
Sertraline Approved Phase 3 79617-96-2 68617
37
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3 21645-51-2
38
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
39
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
40
Flucytosine Approved, Investigational Phase 3 2022-85-7 3366
41
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
42
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
43
Cobalamin Experimental Phase 3 13408-78-1 6857388
44 Vitamin B 12 Phase 3
45 Vitamin B12 Phase 3
46 Antidepressive Agents Phase 3
47 Psychotropic Drugs Phase 3
48 Serotonin Uptake Inhibitors Phase 3
49 Neurotransmitter Agents Phase 3
50 Pharmaceutical Solutions Phase 3

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
2 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
3 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Unknown status NCT02569632 Phase 4
4 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
5 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
6 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Completed NCT02864927 Phase 4
7 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
8 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
9 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
10 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
11 A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
12 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
13 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
14 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
15 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
16 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
17 Evaluation of the Effect of Tetravalent (A, C, Y, W-135) Meningococcal Conjugate Vaccine on Serogroup-Specific Carriage of Neisseria Meningitidis Completed NCT00119080 Phase 4
18 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
19 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
20 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
21 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
22 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
23 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
24 A Sourcing Study to Collect Human Biological (Serum) Samples From Healthy Adults Recruiting NCT03493919 Phase 4
25 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study) Recruiting NCT03682939 Phase 4
26 Multicenter, Randomized, Open-label Non-inferiority Trial, Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte) Not yet recruiting NCT04211649 Phase 4 3 days of antibiotherapy
27 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin Prophylaxis as a Response to a Meningococcal Meningitis Epidemic Withdrawn NCT03431675 Phase 4 Ciprofloxacin
28 A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00474526 Phase 3
29 A Randomized, Open-Label Trial of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants Completed NCT00161928 Phase 3
30 An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercially Available MenACWY Conjugate Vaccine Completed NCT00856297 Phase 3
31 A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine Completed NCT00450437 Phase 3
32 A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea Completed NCT01274897 Phase 3
33 A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents Completed NCT00518180 Phase 3
34 A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine Completed NCT01148017 Phase 3
35 Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed NCT01519713 Phase 3
36 A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28 Completed NCT01894919 Phase 3
37 Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis Completed NCT02305446 Phase 3
38 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers Completed NCT03205371 Phase 3
39 A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age. Completed NCT00474487 Phase 3
40 A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine Completed NCT00310674 Phase 3
41 A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00657709 Phase 3
42 Safety Study of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
43 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers Completed NCT00667602 Phase 3
44 A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years Completed NCT01352793 Phase 3
45 A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10. Completed NCT01148524 Phase 2, Phase 3
46 A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life. Completed NCT01214837 Phase 3
47 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age Completed NCT01755689 Phase 3
48 A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis (Tdap) Vaccine and Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Acellular Pertussis (Tdap) Vaccine, or One Dose of Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years Completed NCT00329901 Phase 3
49 A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults Completed NCT01478347 Phase 3
50 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3

Search NIH Clinical Center for Meningococcal Meningitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chloramphenicol sodium succinate

Cochrane evidence based reviews: meningitis, meningococcal

Genetic Tests for Meningococcal Meningitis

Anatomical Context for Meningococcal Meningitis

MalaCards organs/tissues related to Meningococcal Meningitis:

40
Testes, B Cells, Skin, Brain, Spinal Cord, Breast, Colon

Publications for Meningococcal Meningitis

Articles related to Meningococcal Meningitis:

(show top 50) (show all 1483)
# Title Authors PMID Year
1
[Predisposing factors of community acquired bacterial meningitis (excluding neonates)]. 61 54
19419829 2009
2
[Immunology in the medical practice. XXVII. Mannose-binding lectin, an important link for nonspecific or hereditary immune reaction]. 61 54
10897301 2000
3
Association of familial deficiency of mannose-binding lectin and meningococcal disease. 61 54
10509505 1999
4
Recurrent meningococcal meningitis with complement 6 (C6) deficiency: A case report. 61
32481330 2020
5
Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus. 61
32312231 2020
6
An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis. 61
32178907 2020
7
Validation of a New Rapid Detection Test for Detection of Neisseria meningitidis A/C/W/X/Y Antigens in Cerebrospinal Fluid. 61
31915288 2020
8
Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso. 61
32075630 2020
9
Cerebrospinal meningitis: a global disease with regional variability? 61
32115677 2020
10
COVID-19 and lessons learned from the pandemic wave of meningococcal meningitis (1985-1990). 61
32528206 2020
11
The Origin of the Idea That Herpes Labialis Is of Prognostic Importance in Bacterial Meningitis. 61
32222716 2020
12
Differences in the courses of meningococcal and pneumococcal cerebrospinal meningitis. 61
31956973 2020
13
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery. 61
31762464 2019
14
Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitidis using comprehensive immunoinformatics approaches. 61
31394292 2019
15
A case report of multiple cerebral abscess formation complicating serogroup B Neisseria meningitidis meningitis. 61
31638913 2019
16
Subdural and subarachnoid empyema as a complication of an acute meningococcal meningitis. 61
31630118 2019
17
Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response. 61
31671446 2019
18
Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011-2017. 61
31671449 2019
19
Meningitis vaccines in children: what have we achieved and where next? 61
31335439 2019
20
MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa. 61
31671453 2019
21
Bacterial Meningitis Epidemiology in Five Countries in the Meningitis Belt of Sub-Saharan Africa, 2015-2017. 61
31671441 2019
22
Epidemiology of Bacterial Meningitis in the Nine Years Since Meningococcal Serogroup A Conjugate Vaccine Introduction, Niger, 2010-2018. 61
31671439 2019
23
Neisseria meningitidis Serogroup W Meningitis Epidemic in Togo, 2016. 61
31671438 2019
24
Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential. 61
32335565 2019
25
Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: Analysis of outbreak data from Ghana. 61
29371015 2019
26
A case of a FilmArray® ME false negative in meningococcal meningitis. 61
31102602 2019
27
Meningococcal meningitis presenting postinfant group B meningococcal immunisation. 61
30518518 2019
28
Changes in the Molecular Epidemiology of Pediatric Bacterial Meningitis in Senegal After Pneumococcal Conjugate Vaccine Introduction. 61
31505635 2019
29
Epidemiological burden of meningococcal disease in Latin America: A systematic literature review. 61
31085314 2019
30
Gauging the epidemic potential of a widely circulating non-invasive meningococcal strain in Africa. 61
31454306 2019
31
Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein. 61
31270173 2019
32
A Systematic Review for Vaccine-Preventable Diseases on Ships: Evidence for Cross-Border Transmission and for Pre-Employment Immunization Need. 61
31366029 2019
33
Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review. 61
30937163 2019
34
Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. 61
30987851 2019
35
Increasing the number of contacts generated during contact tracing interviews. 61
30295153 2019
36
Virulence Traits of a Serogroup C Meningococcus and Isogenic cssA Mutant, Defective in Surface-Exposed Sialic Acid, in a Murine Model of Meningitis. 61
30718288 2019
37
Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis. 61
30856166 2019
38
Fatal meningococcal meningitis in a 2-year-old child: A case report. 61
30863763 2019
39
Meningococcal purpura fulminans and severe myocarditis with clinical meningitis but no meningeal inflammation: a case report. 61
30871501 2019
40
Meningococcal Meningitis. 61
30860561 2019
41
Subdural effusion and ischemic stroke complicating meningococcal meningitis in an adult. 61
30497911 2019
42
[Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017]. 61
30744289 2019
43
Pediatric meningococcocal meningitis in the acute phase: how much does it cost? 61
30760306 2019
44
[Efficacy, safety, and cost-effectiveness of meningococcal vaccines]. 61
30744260 2019
45
[Efficacy, safety, and cost-effectiveness of meningococcal vaccines]. 61
30744287 2019
46
[Genotypes of Neisseria meningitidis isolates in patients with meningococcal meningitis in Paraguay, 1996-2015Genótipos de Neisseria meningitidis isolados de pacientes com doença meningocócica no Paraguai, 1996-2015]. 61
31093234 2019
47
Carbohydrates in Vaccine Development. 61
31267872 2019
48
Neisseria meningitidis and cytomegalovirus simultaneous detection in the filmarray meningitis/encephalitis panel and its clinical relevance. 61
31193598 2019
49
Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells as a Cellular Model to Study Neisseria meningitidis Infection. 61
31191497 2019
50
The attitudes, behaviors, and knowledge of healthcare professionals towards the diagnosis, treatment, and prevention of bacterial meningitis in Turkey. 61
30192703 2019

Variations for Meningococcal Meningitis

Expression for Meningococcal Meningitis

Search GEO for disease gene expression data for Meningococcal Meningitis.

Pathways for Meningococcal Meningitis

Pathways related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 TLR9 TLR4 TLR2 MBL2 CFP CFH
2 12.01 TLR9 TLR4 TLR2 C3
3
Show member pathways
11.9 MBL2 CFH C7 C6 C4B C3
4 11.89 TLR4 TLR2 MBL2 C3
5
Show member pathways
11.82 TLR9 TLR4 TLR2
6
Show member pathways
11.73 TLR9 TLR4 TLR2
7
Show member pathways
11.7 MBL2 CFP CFH C7 C6 C4B
8
Show member pathways
11.65 TLR9 TLR4 TLR2
9 11.65 MBL2 CFH C4B C3
10 11.55 TLR4 C4B C3
11 11.55 TLR9 TLR4 TLR2 C3
12
Show member pathways
11.54 MBL2 CFP C7 C6 C4B C3
13 11.41 TLR4 TLR2 C3
14 11.33 MBL2 CFHR2 CFH C7 C6 C4B
15 11.31 TLR9 TLR4 TLR2

GO Terms for Meningococcal Meningitis

Cellular components related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 TLR9 MBL2 CFP CFHR2 CFH C7
2 membrane attack complex GO:0005579 8.96 C7 C6
3 blood microparticle GO:0072562 8.92 INTS11 CFH C4B C3

Biological processes related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10 TLR9 TLR4 TLR2 C4B C3
2 defense response to bacterium GO:0042742 9.96 TLR9 TLR4 MBL2 CFP
3 immune system process GO:0002376 9.96 TLR9 TLR4 TLR2 MBL2 CFP CFH
4 immune response GO:0006955 9.91 TLR9 TLR4 TLR2 CFP C7 C6
5 innate immune response GO:0045087 9.85 TLR9 TLR4 TLR2 MBL2 CFP CFH
6 positive regulation of inflammatory response GO:0050729 9.84 TLR9 TLR4 TLR2
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.81 TLR9 TLR4 TLR2
8 complement activation, classical pathway GO:0006958 9.8 MBL2 C7 C6 C4B C3
9 positive regulation of interleukin-6 production GO:0032755 9.79 TLR9 TLR4 TLR2
10 positive regulation of tumor necrosis factor production GO:0032760 9.79 TLR9 TLR4 TLR2
11 toll-like receptor signaling pathway GO:0002224 9.77 TLR9 TLR4 TLR2
12 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.75 TLR9 TLR4 TLR2
13 positive regulation of interleukin-8 production GO:0032757 9.74 TLR9 TLR4 TLR2
14 positive regulation of interferon-beta production GO:0032728 9.7 TLR9 TLR4 TLR2
15 positive regulation of interleukin-12 production GO:0032735 9.69 TLR9 TLR4 TLR2
16 cytolysis GO:0019835 9.67 C7 C6
17 positive regulation of interleukin-8 secretion GO:2000484 9.67 TLR4 TLR2
18 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 TLR9 TLR4
19 positive regulation of interleukin-10 production GO:0032733 9.67 TLR9 TLR4 TLR2
20 regulation of cytokine secretion GO:0050707 9.66 TLR9 TLR2
21 response to molecule of bacterial origin GO:0002237 9.65 TLR9 TLR2
22 cellular response to lipoteichoic acid GO:0071223 9.65 TLR4 TLR2
23 positive regulation of chemokine production GO:0032722 9.65 TLR9 TLR4 TLR2
24 opsonization GO:0008228 9.64 MBL2 C4B
25 positive regulation of interferon-beta biosynthetic process GO:0045359 9.64 TLR9 TLR4
26 tumor necrosis factor production GO:0032640 9.63 TLR9 TLR2
27 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.63 TLR9 TLR4 TLR2
28 positive regulation of apoptotic cell clearance GO:2000427 9.62 C4B C3
29 complement activation, alternative pathway GO:0006957 9.62 CFP CFH C7 C3
30 I-kappaB phosphorylation GO:0007252 9.61 TLR9 TLR4 TLR2
31 positive regulation of interleukin-18 production GO:0032741 9.6 TLR9 TLR2
32 positive regulation of toll-like receptor signaling pathway GO:0034123 9.58 TLR9 TLR2
33 positive regulation of matrix metallopeptidase secretion GO:1904466 9.56 TLR4 TLR2
34 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.55 TLR4 TLR2
35 positive regulation of activation of membrane attack complex GO:0001970 9.54 C6 C3
36 regulation of complement activation GO:0030449 9.5 CFP CFHR2 CFH C7 C6 C4B
37 complement activation GO:0006956 9.17 MBL2 CFP CFH C7 C6 C4B

Molecular functions related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.26 TLR4 TLR2
2 NAD(P)+ nucleosidase activity GO:0050135 9.16 TLR4 TLR2
3 pattern recognition receptor activity GO:0038187 8.96 TLR9 TLR2
4 lipopolysaccharide receptor activity GO:0001875 8.62 TLR4 TLR2

Sources for Meningococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....